After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, LXEO falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Lexeo Therapeutics Inc is $139.10M. A total of 0.73 million shares were traded on the day, compared to an average of 934.93K shares.
In the most recent transaction, Townsend Richard Nolan sold 1,074 shares of LXEO for 2.77 per share on May 16 ’25. After the transaction, the Chief Executive Officer now owns 221,173 company shares. In a previous transaction on May 16 ’25, Adler Eric sold 585 shares at 2.77 per share. LXEO shares that Chief Medical Officer owns now total 67,681.
Among the insiders who sold shares, Robertson Jenny disposed of 521 shares on May 16 ’25 at a per-share price of $2.77. This resulted in the Chief Legal Officer holding 63,098 shares of LXEO after the transaction. In another insider transaction, See Tai Sandi sold 367 shares at $2.77 per share on May 16 ’25. Company shares held by the Chief Development Officer now total 59,242.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, LXEO has a high of $19.50 and a low of $1.45.
As of this writing, LXEO has an earnings estimate of -$0.65 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of -$0.4 per share and a lower estimate of -$0.81.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. LXEO’s latest balance sheet shows that the firm has $135.86M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $7.45M in liabilities at the time. Its Book Value Per Share was $2.65, while its Total Shareholder’s Equity was -$55.60M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LXEO is Buy with a score of 4.86.
